


Allowed claims in 09/396,523

# ATTACHMENT 1

## Claims on Appeal

1  
3. A N<sup>1</sup>-monosubstituted polyamine analogue or derivative represented by the formula



wherein R is selected from a D or L amino acid; D or L ornithine, ~~an alicyclic, a single or multi-ring aromatic, aliphatic substituted single or multi-ring aromatic~~ and a substituted ~~or unsubstituted~~ single or multi-ring heterocyclic and

Insert 10/13/2005

wherein said analogue or derivative does not have a formula represented by ID 1022, 1043, or 1202.

2  
35. An analogue or derivative according to claim 3 wherein R is a D or L amino acid or D or L ornithine.

34. A composition comprising a polyamine analogue or derivative according to claim 3, 32 or 35 and a pharmaceutically acceptable excipient.

4  
35. A composition comprising a polyamine analogue or derivative according to claim 3, a pharmaceutically acceptable excipient, and an inhibitor of polyamine synthesis.

5  
36. A composition according to claim 35 wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

6  
37. A method for treating a disease or a condition in a subject associated with undesired cell proliferation and/or which is treatable by inhibition of polyamine transport, comprising administering to said subject a polyamine analogue or derivative according to claim 3.

7  
38. A method according to claim 37 wherein said undesired cell proliferation is associated with proliferation of cells of the immune system, cells of the vascular neointima, tumor cells or with undesired angiogenesis.

8  
39. A method according to claim 37 wherein said disease or condition is cancer or post-angioplasty injury.

9  
40. A method according to claim 37 further comprising administration of an inhibitor of polyamine synthesis.

<sup>1</sup>  
~~41~~. A method according to claim <sup>9</sup>~~40~~ wherein said inhibitor of polyamine synthesis is difluoromethylornithine (DFMO).

<sup>1</sup>  
~~42~~. A composition according to claim <sup>4</sup>~~38~~ or <sup>5</sup>~~39~~ in solid form

<sup>1</sup>  
~~43~~. A composition according to claim <sup>4</sup>~~38~~ or <sup>5</sup>~~39~~ in liquid form.

<sup>1</sup>  
~~44~~. A method according to any one of claims <sup>6</sup>~~37-41~~ wherein said administering is performed orally, parenterally, topically, transdermally, intravaginally, intranasally, intrabronchially, intracranially, intraocularly, intraaurally, or rectally, or by injection.

<sup>1</sup>  
~~45~~. A method according to claim <sup>13</sup>~~44~~ wherein said administering by injection is intravenous, subcutaneous, intramuscular, intracranial, or intraperitoneal.

47. A composition comprising a ~~polyamine~~ analogue or derivative according to claim 46 and a pharmaceutically acceptable excipient.

48. A method for treating ~~a disease or a condition~~ in a subject comprising administering to said subject a ~~polyamine~~ analogue or derivative according to claim 46.

add  
C 4 7

---

<sup>15</sup>  
~~49~~. (New) The analogue or derivative of claim <sup>1</sup>~~3~~, wherein said substituted or unsubstituted heterocyclic is a pyrrolidine or a substituted pyrrolidine.

<sup>16</sup>  
~~50~~. (New) The analogue or derivative of claim <sup>15</sup>~~49~~, wherein said substituted pyrrolidine is an N-substituted pyrrolidine.

<sup>17</sup>  
~~51~~. (New) The analogue or derivative of claim <sup>16</sup>~~50~~ represented by the formula ID 1158.

<sup>18</sup>  
~~52~~. (New) The analogue or derivative of claim <sup>1</sup>~~3~~ represented by the formula ID 1224.

<sup>19</sup>  
~~53~~. (New) A method according to claim <sup>6</sup>~~37~~ wherein said condition is associated with cancer.

---